AU experts develop compounds that may boost human memory

Prayagraj: In a breakthrough development, scientists from Allahabad University (AU) have identified 14 chemical compounds that could significantly enhance human memory. These compounds, developed in the university's chemistry laboratory, show promising effects in opening constricted brain neurons, which are often associated with memory loss and cognitive decline.
Tired of too many ads? go ad free now
The research, led by Prof Ramendra Kumar Singh of the Department of Chemistry at AU, marks a major advancement in the search for memory-enhancing drugs. Remarkably, the compounds developed in the Prayagraj-based university are currently undergoing international testing in laboratories in the United States, specifically at California State University, Fullerton.
According to Prof Singh, preliminary results from the testing of three compounds showed positive outcomes, suggesting their potential in combating memory-related disorders.
A research paper detailing this discovery was recently published in the Netherlands-based scientific journal, Journal of Molecular Structure, further highlighting the global relevance of this work. Explaining the scientific basis of the study, Prof Singh said that hyperphosphorylated tau proteins—proteins with an excess of phosphate groups—are responsible for memory degradation in humans.
These proteins accumulate in the brain due to a deficiency of a neurotransmitter called acetylcholine.
The enzyme acetylcholinesterase is responsible for breaking down acetylcholine, thus leading to its depletion.
The 14 newly developed compounds aim to inhibit the function of acetylcholinesterase, thereby maintaining healthy acetylcholine levels and potentially improving memory and brain health. To identify these compounds, the research team conducted a series of chemical reactions in the lab and utilised computational techniques such as molecular docking and computer simulation to evaluate the compounds' activity and cytotoxicity.
Tired of too many ads? go ad free now
The detailed analysis confirmed that all 14 compounds showed significant promise in both effectiveness and safety. These compounds, after being encoded, were sent to California for second-phase testing on specific cell lines known to produce the tau protein responsible for Alzheimer's disease. Although the names of the compounds have not yet been disclosed, Prof Singh noted that the early-stage results are encouraging, with three compounds already delivering positive findings. The next steps in the research include developing a drug based on the most effective molecule. If successful, this could lead to a new therapeutic option for millions suffering from memory loss and neurodegenerative conditions like Alzheimer's.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Hindu

2 hours ago

• The Hindu

Indian private sector in ‘developing' stage: Jitendra Singh

India's private sector was still in a developing stage and would need some time to acquire the 'acumen' to make space vehicles or have biotechnology start-ups grow large enough to invite interest from the public markets, Minister for Science, Space and Atomic Energy Dr. Jitendra Singh said at a press conference on Monday (June 23, 2025). 'We need a robust, developed private sector. There are some that's also because past policy has not favoured the robust development of the private sector. It is only after Prime Minister Narendra Modi came that this has started happening. The space sector opened up to the private sector only four to five years ago, and so their capacity building has started only just now. Several projects have been rolled out, but we don't have the private sector acumen. This will take time, but there is now a shift in the policy,' said Dr. Singh. He was responding to a question from The Hindu on why, despite the government's multiple claims of championing private sector participation in the space sector, no private company was selected to manufacture the Small Satellite Launch Vehicle (SSLV). Last week, public sector defence company Hindustan Aeronautics Limited (HAL) bagged a Transfer of Technology (ToT) deal, valued at ₹511 crore from the Indian Space Research Organisation to build and operate Small Satellite Launch Vehicles (SSLVs). Bidding for SSLV The SSLV is a three-stage vehicle to launch satellites that weigh less than 500 kg into the lower earth orbit (LEO). Apart from the HAL, which had applied independently, two other technically qualified bidders were shortlisted: Alpha Design Technologies Ltd. (ADT), Bengaluru, leading a consortium with Agnikul Cosmos and Walchand Industries Ltd.; and Bharat Dynamics Ltd., Hyderabad, leading a consortium with Skyroot Aerospace, Keltron and Bharat Heavy Electricals Limited (BHEL). ADT is a subsidiary of the Adani conglomerate. Among the three, the HAL emerged as the highest bidder. Dr. Rajesh Gokhale, Secretary, Department of Biotechnology, which oversees the BIRAC (Biotechnology Industry Research Assistance Council) programme that funds biotechnology start-ups since 2012, said that while a start-up listing in the public markets was a sign of success, it was also important to consider market equity. 'The equity of biotechnology start-ups is currently around ₹7,000 have longer incubation periods,' he said in response to a query from The Hindu on when an Indian biotech start-up would hit the public markets. Dr. Singh was addressing a press conference on the achievements of scientific departments — the Departments of Science and Technology, Biotechnology, Council of Scientific and Industrial Research (CSIR), and the Ministry of Earth Sciences.

NDTV

3 hours ago

• NDTV

SpaceX Launches Dog's Ashes To Space On Memorial Flight

A dog's ashes were among the remains sent into space this weekend as part of a memorial mission honouring loved ones by carrying them beyond Earth's atmosphere. Franz, a beloved family Labrador, was among 166 small capsules launched aboard the inaugural Perseverance SpaceX Flight by Texas-based Celestis Inc. The mission lifted off Sunday around 5:30 pm from Vandenberg Space Force Base in Santa Barbara, California. Franz died aged 13 in October 2020. "He was the best dog, just so soft and nice and loved hugs," said the dog's owner Harvin Moore. The pet was more like a sibling to Mr Moore's children, Elizabeth and Quinn. "Now we can't wait to watch our good boy go galactic," he told The NY Post ahead of the launch. The flight lasted about three hours, during which the capsules orbited Earth twice. The rocket then re-entered the atmosphere and splashed down in the Pacific Ocean somewhere between Alaska and Hawaii. A recovery ship, stationed at sea ahead of time, tracked and retrieved the capsules before sending them to Germany for processing. Within two months, the remains will be returned to their families. The cost to send each capsule into space was $3,500 (over Rs 3 lakh). For Franz's owner, the expense was "a lot more" than the dog's value, but entirely worth it for his family of space enthusiasts. Mr Moore said, "The emotional power of being with a group of people who are celebrating the life of a loved one in this way ... it's amazing. It's nothing we'll ever forget. It's just pure joy." Houston-based Celestis has a long history of sending DNA and cremated remains of people, pets, and celebrities into space using rockets like United Launch Alliance's Vulcan Centaur. Their missions have carried iconic figures such as "Star Trek" legends Nichelle Nichols, DeForest Kelley, Gene Roddenberry and his wife Majel Barrett Roddenberry, and James "Scotty" Doohan. They also flew Douglas Trumbull, a visual effects pioneer behind 2001: A Space Odyssey and Close Encounters of the Third Kind, along with symbolic remains of four former US presidents, George Washington, Dwight D Eisenhower, John F Kennedy, and Ronald Reagan, on last year's deep-space Enterprise Flight. Each capsule, crafted from titanium or aluminium and measuring roughly a quarter to half an inch, contained either DNA or cremated remains. These precious capsules orbited Earth twice aboard a 23-foot-tall SpaceX Falcon 9 rocket, travelling at a speed of almost 28,000 kmph in low Earth orbit. Charles Chafer, Celestis CEO and co-founder said Saturday, "Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy." Also aboard the Perseverance Flight were the ashes of Wesley Dreyer, an aerospace engineer involved in investigating the 1986 Space Shuttle Challenger disaster, as well as the DNA of a living three-year-old boy in Germany.

Business Standard

3 hours ago

• Business Standard

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

US-based pharmaceutical company Eli Lilly on Monday announced findings from the Phase 3 clinical trials for its once-weekly investigational insulin drug, efsitora alfa (efsitora), indicating positive safety and efficacy results for A1C reduction compared to daily basal insulin. While basal insulin is a long-acting insulin administered once or twice a day, efsitora is designed for once-weekly subcutaneous injection. The company also shared detailed results from the Phase 3 QWINT-1, QWINT-3 and QWINT-4 trials. The QWINT-1 trial evaluated adults initiating insulin therapy, while QWINT-3 assessed individuals previously using daily basal insulin. QWINT-4 included participants using both basal and mealtime insulin. 'In each study, efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin,' the company stated. According to Lilly, in QWINT-1, efsitora reduced A1C by 1.31 per cent compared to 1.27 per cent for insulin glargine at week 52 for the efficacy estimand. In QWINT-3, the drug reduced A1C by 0.86 per cent compared to 0.75 per cent for insulin degludec at week 26. 'In QWINT-4, efsitora reduced A1C by 1.07 per cent, matching insulin glargine's reduction of 1.07 per cent at week 26 for the efficacy estimand,' Lilly added. The Phase 3 global clinical development programme for the diabetes drug began in 2022 and included over 3,000 participants with type 2 diabetes across four global registration studies. Commenting on the results, Jeff Emmick, senior vice president of product development at Lilly, said that the once-weekly insulin therapy may offer a significant advancement for people with type 2 diabetes who need insulin, by eliminating over 300 injections a year. The company added that the drug also has the potential to provide more stable glucose levels—reducing glucose variability—throughout the week. Eli Lilly now plans to submit the drug to global regulatory agencies for the treatment of type 2 diabetes in adults by the end of 2026.